Jim Simons Sab Biotherapeutics, Inc. Transaction History

Renaissance Technologies LLC

  • $63.1 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024
BUY
$0.62 - $1.0 $3,100 - $5,000
5,000 Added 8.61%
63,100 $43,000
Q3 2023

Nov 14, 2023
BUY
$0.47 - $0.9 $1,739 - $3,330
3,700 Added 6.8%
58,100 $37,000
Q2 2023

Aug 11, 2023
BUY
$0.38 - $1.09 $20,672 - $59,296
54,400 New
54,400 $45,000

Others Institutions Holding SABS

# of Institutions
3
Shares Held
529K
Call Options Held
0
Put Options Held
0
View Full List

About SAB Biotherapeutics, Inc.

SABS Quotes by TradingView
  • Ticker SABS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,030,900
  • Market Cap $133M
  • Description
  • SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases ...
More about SABS
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email